Galbanic acid, a sesquiterpene coumarin from Ferula szowitsiana roots, was investigated for its potentiating effect on the antimicrobial activity of antibiotics as well as ethidium bromide, in 6 multidrug resistance (MDR) clinical isolates of Staphylococcus aureus. Galbanic acid had inhibitory effect on none of the isolated bacteria tested (up to 800 µg /ml). The MIC range of ciprofloxacin, tetracycline and ethidium bromide, against all tested S. aureus were 10-80, 10-80 and 4-16 µg/ml, respectively. These were reduced to 2.5-5, 2.5-5 and 0.5-2 µg/ml in the presence of galbanic acid (300 µg /ml) or verapamil (100 µg /ml). The rate of ethidium bromide (2 µg /ml) accumulation in clinical isolates was enhanced with galbanic acid (300 µg /ml). There is also a decrease in loss of ethidium bromide from bacteria in the presence of galbanic acid. Similar results were obtained when verapamil (100 µg /ml) was used as an efflux pump inhibitor. Galbanic acid, like verapamil, a typical inhibitor of efflux pump, reduced the MIC of ethidium bromide and tested antibiotics. Since efflux is the only known reported mechanism for ethidium bromide resistance, the reduction in ethidium bromide MIC and enhanced accumulation as well as decreased efflux of ethidium bromide in the presence of galbanic acid, can be attributed to this efflux inhibitory properties.
INTRODUCTION
Efflux of antibiotics is a clinically important resistance mechanism for bacteria, often endowing them with multipledrug-resistance (MDR) phenotypes (13) . Efflux pumps may be specific for one substrate or may transport various compounds with different structures (17) . MDR efflux pumps play an important role in antimicrobial resistance, and by removal of the environmental toxins contribute to the bacterial survival (4) . Staphylococcus aureus is a major human pathogen that produces many virulence factors which contribute to its pathogenicity (6, 20) . This bacterium is a cause for considerable concern, because of its ability to acquire resistance towards the currently used antibacterial agents (19) .
S. aureus chromosomes encode a range of MDR transporters.
Several of these efflux pumps have been identified and demonstrated to cause resistance to various compounds (20) .
Fluoroquinolone resistance of several clinical isolates of S.
aureus is provided by the membrane protein NorA encoded in the bacterial chromosome (12, 15) . Also, over-expression of
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NorB leads to decrease in the susceptibility to fluoroquinolones, tetracycline, disinfectants, and dyes (17, 20) .
NorB, can also facilitate bacterial survival, when overexpressed in a staphylococcal abscess. Also it may contribute to the relative resistance of abscesses to antimicrobial therapy, thus linking bacterial fitness and resistance in vivo (4) . It is therefore necessary that new antibiotics, resistance-modifying agents and, more specifically, efflux pumps inhibitors (EPIs) to be identified (19) . The reversal of this resistance, via inhibition of drug efflux mechanisms, is a promising research area. In this regard, extensive studies have been performed in order to obtain new effective resistance modifiers from plants (11) . The use of these natural bacterial resistance modifiers, including
EPIs can facilitate the re-introduction of therapeutically ineffective antibiotics back into clinical use; such as ciprofloxacin, and might even suppress the emergence of MDR strains (19) .
There is a report that driportlandin ( Fig. 1. B) , a sesquiterpene coumarin ether compound, showed a significant effect in inhibiting the efflux pump activity mediated by pglycoprotein as compared with that of verapamil, a known resistance inhibitor (11) . In the present study, we described the effect of galbanic acid, a major plant sesquiterpene coumarin present in Ferula szowitsiana on antimicrobial activity of antibiotics against S. aureus (18), as a modulator of antibiotic resistance on clinical isolates of S. aureus, and its possible inhibitory effect on MDR pumps.
MATERIALS AND METHODS

Materials and bacterial strains
Galbanic acid has been previously isolated and characterized by our group from the roots of Ferula szowitsiana DC., a plant of Apiaceae family ( Fig. 1. A) Plates were incubated at 37ºC for 18 h.
Potentiation of antibiotic activity by galbanic acid
Potentiation studies were performed by a broth checkerboard method (5) . Final bacterial inoculum size in each well was 10 6 CFU/ml. Galbanic acid was tested at serial two fold sub-MIC concentrations (37.5-300 µg/ml), in combination with either antibiotics (2.5-80 µg /ml) or ethidium bromide (0.5-16 µg /ml). The plates were incubated at 37ºC for 18 h. As the positive control, verapamil, a known resistance inhibitor was tested in the same manner at serial two fold dilutions (12.5-100 µg /ml).
Accumulation and efflux of ethidium bromide
Measurement of the level of ethidium bromide accumulation and efflux in 6 clinical multidrug resistant isolates of S. aureus and S. aureus ATCC 6538P was based on previously described method (3, 15, 16) . Briefly, for measurement of the level of accumulation, bacterial suspension with an optical density of 0.2 at 550 nm was prepared in uptake buffer (NaCl, 110 mM; KCl, 7 mM; NH4Cl, 5 mM; Na2HPO4, 0.4 mM; Tris base, 52 mM; glucose 0.2 % adjusted to pH 7.5 with HCl) and was then exposed to ethidium bromide at a concentration of 2 µg/ml. The increase in fluorescence as ethidium bromide entered the cells was recorded fluorometrically with Shimadzu RF-540 spectrofluorimeter ( em = 600 nm, ex = 530 nm) at room temperature. The effect of verapamil and galbanic acid on the level of accumulation was determined in a similar way, after addition of either verapamil (100 µg/ml) or galbanic acid (300 µg/ml) to the uptake buffer. To determine ethidium bromide loss, bacterial suspension was exposed to ethidium bromide (2 µg/ml) for 30 min at 37ºC. The cells were then pelleted by centrifugation and re-suspended in fresh uptake buffer. This process was repeated again in the presence of either verapamil (100 µg /ml) or galbanic acid (300 µg /ml). The loss of ethidium bromide from the cells was measured as a decrease in fluorescence.
RESULTS
Susceptibility testing
Galbanic acid had no inhibitory effect on the bacterial isolates tested (up to 800 µg/ml). The MICs of ciprofloxacin, tetracycline and ethidium bromide, against S. aureus were 10-80, 10-80 and 4-16 µg/ml, respectively. The MEC (minimum effective concentration) for inhibition of ethidium bromide efflux was defined as the lowest amount of either galbanic acid (300 µg/ml) or verapamil (100 µg/ml) which produced the maximum reduction in the MIC. The MICs of ciprofloxacin, tetracycline and ethidium bromide were reduced to less than 2.5-5, 2.5-5 and 0.5-2 µg/ml, respectively, in the presence of either galbanic acid (300 µg/ml) or verapamil (100 µg/ml) ( Table 1) . (Fig. 2) . A decrease in loss of ethidium bromide from bacteria was observed in the presence of galbanic acid (Fig. 3) .
Accumulation and efflux of ethidium bromide
Similar results were obtained when verapamil (100 µg/ml) was used as an efflux pump inhibitor. Galbanic acid as an inhibitor of S. aureus 
